INT125066

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.49
First Reported 2004
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 56
Total Number 58
Disease Relevance 41.55
Pain Relevance 5.42

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (HDAC4) nucleus (HDAC4) transcription factor binding (HDAC4)
cytoplasm (HDAC4)
Anatomy Link Frequency
lung 3
apoptotic cell 1
epithelial cells 1
lymphocytes 1
HeLa 1
HDAC4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 343 100.00 Very High Very High Very High
cytokine 135 100.00 Very High Very High Very High
palliative 8 99.08 Very High Very High Very High
corticosteroid 28 98.80 Very High Very High Very High
Migraine 17 98.72 Very High Very High Very High
Neuropathic pain 6 97.44 Very High Very High Very High
antidepressant 1 95.44 Very High Very High Very High
anticonvulsant 9 95.36 Very High Very High Very High
Inflammatory response 22 94.08 High High
Pain 12 93.84 High High
Disease Link Frequency Relevance Heat
Aging 16 99.92 Very High Very High Very High
Cancer 909 99.86 Very High Very High Very High
Leukemia 95 99.80 Very High Very High Very High
Death 405 99.76 Very High Very High Very High
Shock 24 99.60 Very High Very High Very High
Apoptosis 816 99.54 Very High Very High Very High
Bacterial Respiratory Disease 2 98.80 Very High Very High Very High
Headache 24 98.72 Very High Very High Very High
INFLAMMATION 358 98.68 Very High Very High Very High
Carcinoma 49 98.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
HDAC inhibitors reversed learning and consolidation deficits in ORM in these models.
Negative_regulation (inhibitors) of HDAC
1) Confidence 0.49 Published 2008 Journal Mol. Cell. Neurosci. Section Abstract Doc Link 18638560 Disease Relevance 0.26 Pain Relevance 0.09
Many studies have shown that HDAC inhibitors selectively induce cellular differentiation, growth arrest and apoptosis in cancer cells, making these inhibitors a promising new class of anticancer drugs [15-17].
Negative_regulation (inhibitors) of HDAC associated with cancer and apoptosis
2) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.97 Pain Relevance 0.17
The molecular basis for the action of HDAC inhibitors in caner therapeutics is one of the important questions remaining to be answered.
Negative_regulation (inhibitors) of HDAC
3) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.20 Pain Relevance 0
Our study demonstrates that although the primary target of HDAC inhibitors may be transcription, it is the cellular environment, or the ability of cells to maintain their survival protein networks that determines their fate, to die or to survive in response to the treatment.


Negative_regulation (inhibitors) of HDAC
4) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.94 Pain Relevance 0
Since Akt is a key regulator of cellular survival, we studied the effects of HDAC inhibitors on Akt expression by using quantitative real-time RT-PCR analysis with specific primers and corresponding TaqMan probes for different Akt isoforms.
Negative_regulation (inhibitors) of HDAC
5) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.65 Pain Relevance 0
For targeted or customized cancer therapy, it is essential to understand the distinct mechanisms of apoptotic cell death induced by HDAC inhibitors.
Negative_regulation (inhibitors) of HDAC in apoptotic cell associated with cancer, apoptosis and death
6) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 1.03 Pain Relevance 0
The efficacy of HDAC inhibitors in cancer therapeutics may well come from restoring silenced gene expression since transcription is the primary target of HDAC inhibitors.
Negative_regulation (inhibitors) of HDAC associated with cancer
7) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 1.28 Pain Relevance 0
Our study demonstrated that HDAC inhibitors, such as valproic acid and butyrate, induce apoptosis in HeLa cervical cancer cells by inhibition of gene expression of Akt1 and Akt2.
Negative_regulation (inhibitors) of HDAC in HeLa associated with cervical cancer and apoptosis
8) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 1.04 Pain Relevance 0
Caspase-8 can be activated by HDAC inhibitors through the death receptors in several cancer cell lines [42-44].
Negative_regulation (inhibitors) of HDAC associated with cancer and death
9) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.78 Pain Relevance 0
This deregulation of Akt may sensitize cancer cells to HDAC inhibitors.
Negative_regulation (inhibitors) of HDAC associated with cancer
10) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.57 Pain Relevance 0
Numerous studies have shown that, through its chromatin remodeling activities, HDAC inhibitors are capable of modulating gene transcription involved in various cellular processes such as cell cycle progression, differentiation and apoptosis [15].
Negative_regulation (inhibitors) of HDAC associated with apoptosis
11) Confidence 0.23 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 1.26 Pain Relevance 0
If transcription is the primary target of HDAC inhibitors, then normal cells should be equally if not more susceptible toward the HDAC inhibitors.
Negative_regulation (inhibitors) of HDAC
12) Confidence 0.20 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.26 Pain Relevance 0
HDAC inhibitors, inducers of differentiation or apoptosis of some cervical and ovarian cancer cells, have become a new class of drugs for treatment of a variety of cancers [17].
Negative_regulation (inhibitors) of HDAC associated with cancer, ovarian cancer and apoptosis
13) Confidence 0.20 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.55 Pain Relevance 0
In both 87MG and PC3 cells, treatment with HDAC inhibitors decreases the levels of Akt phosphorylation [49].
Negative_regulation (inhibitors) of HDAC
14) Confidence 0.20 Published 2006 Journal Mol Cancer Section Body Doc Link PMC1762018 Disease Relevance 0.66 Pain Relevance 0
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Negative_regulation (inhibitor) of histone deacetylase associated with carcinoma and palliative
15) Confidence 0.15 Published 2010 Journal Lancet Oncol. Section Title Doc Link 20378407 Disease Relevance 0.10 Pain Relevance 0.19
In addition, a decreased level of acetylation as a result of increased histone deacetylase activity has also been observed [30].
Negative_regulation (decreased) of histone deacetylase
16) Confidence 0.15 Published 2010 Journal Invest New Drugs Section Body Doc Link PMC3003795 Disease Relevance 1.16 Pain Relevance 0.16
Novel therapeutic approaches are now being developed to target some of these molecular lesions, including epigenetic alterations, by making use of methyltransferase and histone deacetylase inhibitors.
Negative_regulation (inhibitors) of histone deacetylase
17) Confidence 0.15 Published 2010 Journal Invest New Drugs Section Body Doc Link PMC3003795 Disease Relevance 1.31 Pain Relevance 0.07
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Negative_regulation (inhibitors) of Histone deacetylase associated with inflammation, disease and cytokine
18) Confidence 0.13 Published 2005 Journal Drug Discov. Today Section Title Doc Link 15708534 Disease Relevance 0.69 Pain Relevance 0.49
A large, multicenter, phase 3 ECOG study evaluating the combination of azacitidine with MS-275, a histone deacetylase inhibitor, is currently underway based on promising phase 1 combination data.
Negative_regulation (inhibitor) of histone deacetylase
19) Confidence 0.12 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2939768 Disease Relevance 0.56 Pain Relevance 0
In cancer cells inhibition of histone deacetylase activity can cause growth arrest and apoptosis, and thus inhibit carcinogenesis [53].
Negative_regulation (inhibition) of histone deacetylase associated with cancer and apoptosis
20) Confidence 0.10 Published 2004 Journal J Carcinog Section Body Doc Link PMC421747 Disease Relevance 0.51 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox